Secukinumab: A Review in Psoriatic Arthritis

@article{Shirley2016SecukinumabAR,
  title={Secukinumab: A Review in Psoriatic Arthritis},
  author={Matt Shirley and Lesley J. Scott},
  journal={Drugs},
  year={2016},
  volume={76},
  pages={1135-1145}
}
Secukinumab (Cosentyx®) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. It is the first-in-class anti-IL-17 agent, initially approved for the treatment of plaque psoriasis, and more recently for the treatment of ankylosing spondylitis and psoriatic arthritis. This article reviews the therapeutic efficacy of subcutaneous secukinumab in the treatment of psoriatic arthritis, as well as discussing the tolerability and pharmacological properties of the drug… 
Secukinumab: A Review in Psoriatic Arthritis
TLDR
Secukinumab is effective across all key PsA domains and is generally well tolerated, and thus represents a useful treatment alternative to TNFi and other bDMARDs in adult patients with active PsA.
Secukinumab: A Review in Ankylosing Spondylitis
TLDR
In ongoing phase III trials, 16 weeks’ treatment with subcutaneous secukinumab 150 mg was effective in terms of improving the clinical signs and symptoms of disease and health-related quality of life in patients with AS, with these improvements maintained during longer-term treatment.
Secukinumab: A Review in Ankylosing Spondylitis
TLDR
Secukinumab is an effective therapy for TNF inhibitor-naive patients with active AS, and provides a useful treatment option for patients who have an inadequate response to or are intolerant of TNF inhibitors.
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
TLDR
Treatment with secukinumab provided fast and durable skin clearance and continuous improvements in health-related quality of life in children and adolescents aged 6 to < 18 years with moderate to severe plaque psoriasis.
Tofacitinib: A Review in Psoriatic Arthritis
TLDR
Current available evidence indicates that tofacitinib expands the treatment options available for the treatment of PsA in patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
Treatment with secukinumab in multi-comorbid patients with psoriatic arthritis
TLDR
Although this case series is limited in size, the results may be reassuring on the low risk of candida infection in psoriatic patients, during secukinumab therapy.
Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis
TLDR
In real life, in biologic-experienced patients with PsA, SEC displayed a high retention rate, regardless of the type, and number of previous biologics (anti-TNFs ± anti-IL12/23), without significant side effects.
Updated therapies for the management of psoriatic arthritis.
TLDR
An overview of the landscape of drug therapies, including IL-17,IL-12/23, IL-23 inhibitors, and janus kinase (JAK) inhibitors, as well as those in development, such as RORγt inhibitors, anti-NGF agents, mTOR inhibitors and T cell ion-channel blockers are provided.
Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
TLDR
SEC showed a good retention rate in a population previously exposed to several biological therapies and as a novelty, cardiometabolic comorbidities were associated with better drug survival.
Systemic rheumatic diseases: From biological agents to small molecules.
The development of biologics and small oral molecules has recently changed the scenario of pharmacologic treatment of systemic rheumatic diseases and it has become a real revolution. These drugs have
...
1
2
3
...

References

SHOWING 1-10 OF 48 REFERENCES
Secukinumab: A Review in Ankylosing Spondylitis
TLDR
In ongoing phase III trials, 16 weeks’ treatment with subcutaneous secukinumab 150 mg was effective in terms of improving the clinical signs and symptoms of disease and health-related quality of life in patients with AS, with these improvements maintained during longer-term treatment.
Secukinumab: A New Treatment Option for Psoriatic Arthritis
TLDR
Clinical studies with secukinumab provide significant and sustained reductions in the signs and symptoms of PsA, inhibition of radiographic progression, and improved patient-reported outcomes and measures of quality of life, and offer an effective new addition to the available treatment options for PsA.
Secukinumab: A Review in Moderate to Severe Plaque Psoriasis
TLDR
Subcutaneous secukinumab is an effective and generally well tolerated first-line treatment for moderate to severe plaque psoriasis, and is a useful addition to the treatment options for this disease.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
TLDR
Secuk inumab was more effective than placebo in patients with psoriatic arthritis, which validates interleukin-17A as a therapeutic target, and secondary end points, including the ACR50 response and joint structural damage, were significantly better in the secukinumab groups than in the placebo group.
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
TLDR
Secukinumab at a subcutaneous dose of 150 mg, with either sub cutaneous or intravenous loading, provided significant reductions in the signs and symptoms of ankylosing spondylitis at week 16, and was sustained through 52 weeks.
Advances in the management of psoriatic arthritis
TLDR
Psoriatic arthritis management must now use improved measures to predict patient outcomes and define remission, and develop better-targeted therapies.
Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
TLDR
Secukinumab 300 mg produced significant improvement in psoriasis and physical functioning in subjects with concomitant PsA.
A short history of biological therapy for psoriatic arthritis.
  • P. Mease
  • Medicine
    Clinical and experimental rheumatology
  • 2015
TLDR
New medicines which target other key cytokines and immunologic pathways, including ustekinumab which inhibits both IL12 and IL23 and thus is felt to work in both the TH1 and TH7 pathways of inflammation, has been approved for the treatment of PsA as well as psoriasis.
Secukinumab Reverses Disease-Defining Psoriasis Histopathology While Retaining Full T-cell Activation Potential
TLDR
The effects of secukinumab on skin pathology and T cell activation were investigated and the primary endpoint was histological disease reversal at Week 12.
Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis
TLDR
UST, SEC and APR are new drugs with efficacy demonstrated for the treatment of PsA and, in general, safety appeared satisfactory, but long-term studies are needed.
...
1
2
3
4
5
...